Search the Newsreel

Unicycive Therapeutics (UNCY) director granted 47,941 RSUs with staged vesting

Unicycive Therapeutics director Sara Kenkare-Mitra was granted 47,941 Restricted Stock Units (RSUs) on May 14, 2026. Of these, 19,976 shares vested immediately, and the remaining 3,995 shares will vest monthly over seven months, starting June 1, 2026, contingent upon her continued service. The transaction, …

Freetech Road Recycling Technology (Holdings) Ltd. Revenue Breakdown – HKEX:6888

PureCycle Technologies and IPL Schoeller develop polypropylene tubs and lids with 25% PCR content

PureCycle Technologies and IPL Schoeller are collaborating to develop polypropylene tubs and lids that incorporate 25% post-consumer recycled (PCR) content. This initiative aims to help brands like Cleveland Kitchen comply with emerging recycled-content packaging mandates in various U.S. states. The PureFive resin used is …

Pure Cycle Corp (PCYO) Institutional Confidence

Pure Cycle Corp (PCYO) has an institutional shareholding score of 7.00, placing it 5th out of 14 in the Water & Related Utilities industry. Institutional shareholding percentage rose by 7.36% quarter-over-quarter to 76.55%. ETHSX is the largest institutional shareholder with 134.25K shares, representing 0.56% …

ETFs Investing in Pure Cycle Corporation Stocks

This article provides a list of ETFs that hold Pure Cycle Corporation (PCYO) stocks, detailing their market value, weight, issuer, management style, and performance metrics. It offers investors insights into various ETFs, including iShares Microcap ETF and WisdomTree U.S. SmallCap Fund, as a way …

Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Bicycle Therapeutics PLC (BCYC), detailing its business segments, regional revenue, and profit contribution. However, it states that the relevant financial data for these categories has not yet been disclosed by the company. The page also includes current …

Cyclopharm Revenue Surges 74% in US Market as Technegas Installations Double to 70 Sites

Pure Cycle Corp (PCYO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Pure Cycle Corp (PCYO), noting its current valuation score of 6.91, which ranks 5th in its industry. The company's P/E ratio is currently 18.15. The article indicates that relevant data for P/B, P/S, and P/CF ratios have …

Bicycle Therapeutics PLC (BCYC) Cash Flow

This article provides the quarterly and annual cash flow statements for Bicycle Therapeutics PLC (BCYC), detailing operating, investing, and financing cash flows. It includes historical data reaching back to 2017Q4 and highlights key financial metrics such as net income from continuing operations, capital expenditures, …

Bicycle Therapeutics PLC (BCYC) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Bicycle Therapeutics PLC (BCYC)'s dividend and stock split history, indicating that the company has not distributed any dividends over the past five years. It also includes current stock performance data, showing BCYC trading at $3.960 with a 2.33% …

Unicycive Therapeutics Inc (UNCY) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Unicycive Therapeutics Inc (UNCY), noting its current valuation score of 6.30, which ranks 341 out of 386 in the Biotechnology & Medical Research industry. The company's current P/E ratio is -2.28, significantly below its recent high. Key …

PureCycle, Mitsui announce strategic partnership with RM Tohcello to bring recycled polypropylene to flexible packaging in Japan

PureCycle Technologies, Mitsui & Co. Ltd., and RM Tohcello Co. Ltd. have formed a strategic partnership to introduce recycled polypropylene into flexible packaging in Japan. Initial trials with PureCycle's PureFive resin have shown promising results for biaxially oriented polypropylene (BOPP) film, a segment historically …

Unicycive Therapeutics, Inc. Revenue Breakdown – NASDAQ:UNCY

This page provides financial information for Unicycive Therapeutics, Inc. (UNCY) on the Nasdaq Stock Market. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment breakdown options. The content itself seems to be a template for financial data presentation …

PCT|Purecycle Technologies Inc|Price:5.990|Chg%:+0.140

PureCycle Technologies, Inc. is commercializing a patented purification recycling technology to convert waste polypropylene into near-virgin resin, known as PureFive resin. The process involves feed pre-processing, purification using solvent, temperature, and pressure, and compounding to meet customer specifications. The company's stock symbol is PCT, …

Purecycle Technologies Inc (PCT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Purecycle Technologies Inc (PCT), identifying its major individual shareholders and the types of entities holding its shares. It also provides a quarterly breakdown of institutional holdings and lists related ETFs that include PCT in their portfolios.

Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026)

This article reports on an SEC filing from Cyclerion Therapeutics, Inc. (CYCN), specifically an "EFFECT" filing with an effectiveness date of July 24, 2026. The filing is a Form S-4, related to a business combination registration. It also provides the company's stock overview, recent …

Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article focuses on the revenue breakdown for Cyclerion Therapeutics Inc (CYCN), highlighting that the company has not yet disclosed relevant data regarding its business segments or regional revenue and profit contributions. The page provides current stock performance details for CYCN, but the core …

Purecycle Technologies Inc (PCT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Purecycle Technologies Inc (PCT). It indicates that the company has not distributed any dividends over the past five years. The page displays PCT's current stock price, market cap, and offers an overview …

Purecycle Technologies Inc (PCT) Income Statement

This article presents the quarterly and annual income statements for Purecycle Technologies Inc (PCT), detailing revenue, operating expenses, profits, and net income figures across various fiscal periods. It also includes an FAQ section explaining how to interpret financial statements, key metrics for stock analysis, …

Unicycive Therapeutics Inc (UNCY) Cash Flow

This article provides a detailed look at Unicycive Therapeutics Inc's (UNCY) cash flow statements, including operating, investing, and financing activities, spanning from FY2019Q4 to FY2026Q1. It presents quarterly and annual financial data, highlighting changes in net income, working capital, capital expenditures, and cash balances …

PCYO|Pure Cycle Corp|Price:10.610|Chg%:-0.090

Pure Cycle Corporation is a diversified company operating in wholesale water and wastewater services, land development, and single-family home rentals, primarily in the Denver, Colorado area. The company's segments include water and wastewater services and land development, which encompasses master-planned communities and single-family rental …

Cycurion Inc (CYCU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Pure Cycle Corporation Revenue Breakdown – NASDAQ:PCYO

Pure Cycle Corp (PCYO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical payout information for Pure Cycle Corp (PCYO) dividends and stock splits. It notes that no dividend data is available, with a total of $0.00 having been distributed over the past five years. The page also presents current stock data including …

TradingKey

This article provides a detailed quarterly and annual income statement for Bicycle Therapeutics PLC (BCYC), spanning from FY2017Q4 to FY2026Q1. It breaks down various financial metrics including total revenue, operating expenses, R&D expenses, operating profit, non-operating income/expenses, income before tax, income tax, net income, …

BCYC|Bicycle Therapeutics PLC|Price:3.870|Chg%:-0.070

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing a new class of medicines called Bicycle molecules for underserved diseases. The company is evaluating several drug candidates, including zelenectide pevedotin, BT5528, and BT7480, in clinical trials for oncology. They are also exploring …

Metal recycling stocks to buy: Gravita, Pondy Oxides, Jain Resource among top picks

Purecycle Technologies Inc (PCT) Q3 2023 Earnings Report - Results, Call & Slides

PureCycle Technologies (PCT) announced its Q3 2023 earnings, reporting an actual EPS of $0.53, significantly beating the consensus of -$2.77. However, the company missed revenue expectations, reporting $0.00 against an expected $88.65 million. The report includes details on the earnings call, an audio recording, …

Bicycle Therapeutics PLC (BCYC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Bicycle Therapeutics PLC (BCYC), outlining major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. The data includes the …

How PureCycle’s Japan BOPP Film Partnership Could Broaden Its Market Opportunity for Investors (PCT)

PureCycle Technologies has announced a partnership with RM TOHCELLO Co., Ltd. and Mitsui & Co., Ltd. to develop high-purity recycled polypropylene for BOPP film in Japan, a difficult packaging format for recycled content. This collaboration could expand PureCycle’s market and strengthens its long-term investment …

Bicycle Therapeutics PLC (BCYC) Institutional Confidence

Bicycle Therapeutics PLC (BCYC) has an institutional shareholding score of 5.00, placing it 132nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 67.23%, a decrease of 41.32% quarter-over-quarter. James Simons is the largest institutional shareholder despite a decrease in holdings.

Bicycle Therapeutics PLC (BCYC) Financial Health: Profitability & Balance Sheet Analysis

Bicycle Therapeutics PLC (BCYC) has a current financial score of 6.38, ranking 257 out of 386 in its industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 91.11% year-over-year to $887.00K, while net profit saw a 0.12% …

CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025

This article provides an in-depth analysis of Cyclerion Therapeutics Inc (CYCN), highlighting its market trends, real-time quotes, and trading strategies. It details the company's financial performance, key figures, and a score indicating healthy fundamentals and high growth potential despite its valuation being considered fairly …

Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Unicycive Therapeutics Inc's (UNCY) shareholder structure, listing major shareholders by proportion and categorizing shareholders by type such as hedge funds and venture capital. It also presents institutional shareholding trends over several quarters, showing changes in the number …

Cyclerion Therapeutics Inc (CYCN) Institutional Confidence

This article provides an overview of Cyclerion Therapeutics Inc (CYCN) and its institutional confidence score. It includes the stock's current trading price, market capitalization, and a table detailing institutional shareholdings and changes in shares held by various entities and individuals. The institutional confidence score …

UNCY|Unicycive Therapeutics Inc|Price:5.410|Chg%:-0.050

Unicycive Therapeutics Inc (UNCY) is a biotechnology company focused on developing treatments for kidney diseases, with its lead drug candidate, oxylanthanum carbonate (OLC), targeting hyperphosphatemia in dialysis patients, and UNI-494 for acute kidney injury. The article provides current stock information, company details including key …